

ASX Release

New Project Director for Anagrelide Project

PERTH, AUSTRALIA – 14 August 2019: SUDA Pharmaceuticals Ltd (ASX: SUD), a leader in oro-mucosal drug delivery, is pleased to announce that Dr Richard Franklin has joined SUDA as Project Director for the company’s development of anagrelide, an adjunctive oro-mucosal therapy that current research suggests could improve survival as well as the performance of immunotherapeutic treatments currently making their way to market.

On a stand-alone consideration, research to date shows anagrelide reduces the elevated platelet count, a beneficial step as high platelet count plays a key role in in the growth and metastatic spread of cancerous tumours. Like the process of immunotherapy, anagrelide research has also shown that it “un-hides” invading cancerous cells so that the immune system can fight them.

Dr Franklin has over forty years’ experience in pharmaceutical research and development.

He has worked in senior roles with Glaxo, Wyeth, Sterling Winthrop & latterly, Shire Pharmaceuticals where he was Research Fellow & Head of New Product Innovation (small molecules). He is credited with filing over forty patents on potential new drug products. During his career he has published over sixty scientific papers and was associate editor of the journal Xenobiotica for ten years. He is a past chairman and secretary of the European Drug Metabolism Discussion Group.

He was very much involved in the development and EU registration of anagrelide as Xagrid® for the treatment of the orphan drug condition, Essential Thrombocythemia. His drug development experience covers a wide range of different products and therapeutic areas and is thereby eminently qualified to lead this exciting new venture in repurposing anagrelide in the fight against cancer.

Dr Franklin will oversee the anagrelide project through to the completion of the Phase 1 clinical studies. He will be working with SUDA’s project team and engaging with world experts and key opinion leaders on anagrelide. Dr Franklin is based in the United Kingdom and has spent the last week in Perth working with the project team and management.

Dr Franklin is currently a member of SUDA’s Science Advisory Board.



Further information:

STEPHEN CARTER

CHIEF EXECUTIVE OFFICER / MANAGING DIRECTOR

SUDA Pharmaceuticals Ltd

Tel: +61 8 6142 555

sjcarter@sudapharma.com

NOTES TO EDITORS:

About SUDA Pharmaceuticals Ltd

SUDA Pharmaceuticals Ltd (ASX: SUD) is a drug delivery company focused on oro-mucosal administration, headquartered in Perth, Western Australia. The Company is developing low-risk oral sprays using its OroMist® technology to reformulate existing pharmaceuticals. The many potential benefits of administering drugs through the oral mucosa (i.e.: cheeks, tongue, gums and palate) include ease of use, lower dosage, reduced side effects and faster response time. SUDA's product pipeline includes ZolpiMist™, a first-in-class oral spray of zolpidem for insomnia. ZolpiMist is marketed in the USA and SUDA has rights to the product outside of the US and Canada. Other products in development include oral sprays for the treatment of: migraine headache; chemotherapy-induced nausea and vomiting; erectile dysfunction; PAH; epileptic seizures and pre-procedural anxiety; and cancer. SUDA is also fully licensed to purchase and manufacture cannabinoid products. For more information, visit www.sudapharma.com

About blood platelets in cancer

Cancer survival across all solid tumour types has been shown to be related to the number of blood platelets a patient has, cells which are more usually associated with the clotting process. However, platelets are now known to provide essential growth factors that nourish cancer cells and enable them to take hold and develop into tumours. Hence, those patients with the highest platelet numbers are least likely to survive. This has been shown across a wide range of solid tumours including cancer of the brain, oral cavity, the head and neck, thyroid carcinoma, gastrointestinal cancers, pancreatic, hepatocellular cancer, colorectal cancer, cancer of the lungs and bronchus, cancer of the ovaries, endometrium, cervix, breast, prostate, kidneys, skin mesothelioma, melanoma and gallbladder.

About Anagrelide

The pharmacology of anagrelide enables the selective lowering of platelet numbers without significantly affecting clotting or the formation of other blood cell lines and, in this respect, is unique. Currently anagrelide is only available as a solid oral formulation and is used exclusively as an anti-thrombotic agent. The drug's fundamental limitation which precludes its use in the treatment of cancer is its cardio-stimulatory side-effect profile. These effects are known to be due to a highly potent cardio-excitatory metabolite of the drug formed in large quantities during its initial passage through the liver after oral administration. The use of proprietary non-enteral formulation such as an oro-mucosal spray would minimise this first pass effect in the liver.